Patents by Inventor Roman Messerschmid

Roman Messerschmid has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10398654
    Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: September 3, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Masanori Ito, Kenji Egusa, Roman Messerschmid, Peter Schneider
  • Patent number: 10105323
    Abstract: The present invention relates to a pharmaceutical dosage form delivering an immediate release profile containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: October 23, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Roman Messerschmid, Peter Lach, Torsten Sokoliess, Peter Stopfer, Dirk Trommeshauser
  • Publication number: 20180185291
    Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.
    Type: Application
    Filed: February 27, 2018
    Publication date: July 5, 2018
    Inventors: Masanori ITO, Kenji EGUSA, Roman MESSERSCHMID, Peter SCHNEIDER
  • Patent number: 9907756
    Abstract: The present invention relates to a suspension formulation containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate, to a capsule pharmaceutical dosage form containing said suspension formulation, to a process for preparing said suspension formulation, to a process for preparing said capsule comprising said suspension formulation and to the packaging material for the finished capsule.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: March 6, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Roman Messerschmid, Rudolf Binder, Thomas Bock, Werner Brox
  • Publication number: 20170239191
    Abstract: The present invention relates to a pharmaceutical dosage form delivering an immediate release profile containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate.
    Type: Application
    Filed: May 9, 2017
    Publication date: August 24, 2017
    Inventors: Roman MESSERSCHMID, Peter LACH, Torsten SOKOLIESS, Peter STOPFER, Dirk TROMMESHAUSER
  • Publication number: 20170095424
    Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.
    Type: Application
    Filed: December 15, 2016
    Publication date: April 6, 2017
    Inventors: Masanori ITO, Kenji EGUSA, Kyle KLEINBECK, Roman MESSERSCHMID, Peter SCHNEIDER, Venkata VOLETI
  • Publication number: 20170065529
    Abstract: The present invention relates to a pharmaceutical dosage form delivering an immediate release profile containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate.
    Type: Application
    Filed: September 9, 2015
    Publication date: March 9, 2017
    Inventors: Roman MESSERSCHMID, Peter LACH, Thorsten SOKOLIESS, Peter STOPFER, Dirk TROMMESHAUSER
  • Patent number: 9555001
    Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: January 31, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Masanori Ito, Kenji Egusa, Kyle Kleinbeck, Roman Messerschmid, Peter Schneider, Venkata Voleti
  • Publication number: 20160324791
    Abstract: The present invention relates to a suspension formulation containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl -methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate, to a capsule pharmaceutical dosage form containing said suspension formulation, to a process for preparing said suspension formulation, to a process for preparing said capsule comprising said suspension formulation and to the packaging material for the finished capsule.
    Type: Application
    Filed: July 7, 2016
    Publication date: November 10, 2016
    Inventors: Roman MESSERSCHMID, Rudolf BINDER, Thomas BOCK, Werner BROX
  • Publication number: 20160235680
    Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.
    Type: Application
    Filed: April 28, 2016
    Publication date: August 18, 2016
    Inventors: Masanori ITO, Kenji EGUSA, Roman MESSERSCHMID, Peter SCHNEIDER
  • Publication number: 20160022672
    Abstract: The present invention relates to a suspension formulation containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate, to a capsule pharmaceutical dosage form containing said suspension formulation, to a process for preparing said suspension formulation, to a process for preparing said to capsule comprising said suspension formulation and to the packaging material for the finished capsule.
    Type: Application
    Filed: October 7, 2015
    Publication date: January 28, 2016
    Inventors: Roman MESSERSCHMID, Rudolf BINDER, Thomas BOCK, Werner BROX
  • Publication number: 20140163040
    Abstract: The present invention relates to a pharmaceutical dosage form delivering an immediate release profile containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate.
    Type: Application
    Filed: February 10, 2014
    Publication date: June 12, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Roman MESSERSCHMID, Peter LACH, Thorsten SOKOLIESS, Peter STOPFER, Dirk TROMMESHAUSER
  • Publication number: 20140004187
    Abstract: The present invention relates to a suspension formulation containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate, to a capsule pharmaceutical dosage form containing said suspension formulation, to a process for preparing said suspension formulation, to a process for preparing said capsule comprising said suspension formulation and to the packaging material for the finished capsule.
    Type: Application
    Filed: August 30, 2013
    Publication date: January 2, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Roman MESSERSCHMID, Rudolf BINDER, Thomas BOCK, Werner BROX
  • Patent number: 8545884
    Abstract: The present invention relates to a pharmaceutical dosage form containing the active substance BIBW 2992 as the dimaleate salt, providing an immediate release profile of the active substance, further, the invention relates to compacted intermediates comprising BIBW 2992 dimaleate salt (BIBW 2992 MA2) in form of a powder prepared using a combined roller compaction and sieving step from BIBW 2992 MA2, intermediate blends prepared from said compacted intermediate as well as solid oral formulations providing an immediate release profile of the active substance, made from said compacted intermediate or from said intermediate blends ready for use/ingestion, e.g. capsule and tablet formulations such as uncoated or film-coated tablets prepared by direct-compression, and methods for their production.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: October 1, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Roman Messerschmid, Thomas Friedl
  • Publication number: 20130236543
    Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.
    Type: Application
    Filed: March 5, 2013
    Publication date: September 12, 2013
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Masanori ITO, Kenji EGUSA, Kyle KLEINBECK, Roman MESSERSCHMID, Peter SCHNEIDER, Venkata VOLETI
  • Publication number: 20130203773
    Abstract: The present invention relates to a pharmaceutical dosage form delivering an immediate release profile containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate.
    Type: Application
    Filed: March 8, 2013
    Publication date: August 8, 2013
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Roman MESSERSCHMID, Peter LACH, Thorsten SOKOLIESS, Peter STOPFER, Dirk TROMMESHAUSER
  • Publication number: 20130064887
    Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.
    Type: Application
    Filed: March 7, 2012
    Publication date: March 14, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Masanori ITO, Kenji EGUSA, Roman MESSERSCHMID, Peter SCHNEIDER
  • Publication number: 20110301177
    Abstract: The present invention relates to a suspension formulation containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate, to a capsule pharmaceutical dosage form containing said suspension formulation, to a process for preparing said suspension formulation, to a process for preparing said capsule comprising said suspension formulation and to the packaging material for the finished capsule.
    Type: Application
    Filed: June 4, 2009
    Publication date: December 8, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Roman Messerschmid, Rudolf Binder, Thomas Bock, Werner Brox
  • Publication number: 20110190318
    Abstract: The present invention relates to a pharmaceutical dosage form delivering an immediate release profile containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate.
    Type: Application
    Filed: June 4, 2009
    Publication date: August 4, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Roman Messerschmid, Peter Lach, Torsten Sokoliess, Peter Stopfer, Dirk Trommeshauser
  • Publication number: 20110142929
    Abstract: The present invention relates to a pharmaceutical dosage form containing the active substance BIBW 2992 as the dimaleate salt, providing an immediate release profile of the active substance, further, the invention relates to compacted intermediates comprising BIBW 2992 dimaleate salt (BIBW 2992 MA2) in form of a powder prepared using a combined roller compaction and sieving step from BIBW 2992 MA2, intermediate blends prepared from said compacted intermediate as well as solid oral formulations providing an immediate release profile of the active substance, made from said compacted intermediate or from said intermediate blends ready for use/ingestion, e.g. capsule and tablet formulations such as uncoated or film-coated tablets prepared by direct-compression, and methods for their production.
    Type: Application
    Filed: June 5, 2009
    Publication date: June 16, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Roman Messerschmid, Thomas Friedl